RFP
ELDN icon

Root Financial Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Root Financial Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$339 Buy
+110
New +$259 ﹤0.01% 2988

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Root Financial Partners's ELDN Position: Q1 2026 in Review

Root Financial Partners opened a new position in Eledon Pharmaceuticals (ELDN) in Q1 2026: 110 shares worth $339. The stake represents ﹤0.01% of the portfolio and ranks #2988 among its holdings.

121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Root Financial Partners held 110 shares of Eledon Pharmaceuticals worth $339 as of Q1 2026.
  • Eledon Pharmaceuticals was a new Root Financial Partners position in Q1 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of Root Financial Partners's portfolio in Q1 2026, its #2988 holding.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Root Financial Partners's 13F filing for Q1 2026, filed 24 Apr 2026.